Weekly Analysts’ Ratings Changes for AnaptysBio (ANAB)

A number of firms have modified their ratings and price targets on shares of AnaptysBio (NASDAQ: ANAB) recently:

• 3/6/2026 – AnaptysBio had its price target raised by Truist Financial Corporation from $36.00 to $50.00. They now have a “hold” rating on the stock.
• 3/5/2026 – AnaptysBio had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a “buy” rating on the stock.
• 3/4/2026 – AnaptysBio had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an “overweight” rating on the stock.
• 3/4/2026 – AnaptysBio had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a “buy” rating on the stock.
• 1/23/2026 – AnaptysBio was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 1/21/2026 – AnaptysBio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – AnaptysBio had its price target raised by Barclays PLC from $55.00 to $78.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at AnaptysBio

In other news, CEO Daniel Faga sold 15,309 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $43.26, for a total transaction of $662,267.34. Following the completion of the transaction, the chief executive officer directly owned 458,139 shares in the company, valued at $19,819,093.14. This trade represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Magda Marquet sold 11,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the transaction, the director owned 9,930 shares in the company, valued at $478,923.90. This represents a 52.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 156,280 shares of company stock worth $7,254,939 in the last quarter. 33.50% of the stock is currently owned by company insiders.

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.